Crystal problem highlighted in US complete response to Neupro
This article was originally published in Scrip
UCBneeds to resolve the issue of crystal formation in its patch formulation of rotigotine (Neupro) before it can be approved in the US for advanced Parkinson's disease and primary restless legs syndrome (RLS), the FDAhas told the company in a complete response letter.
You may also be interested in...
Jazz and PharmaMar need to see what further data will be needed to convert their FDA authorization into a full approval following disappointing results in the ATLANTIS Phase III trial.
Another disappointment for irritable bowel syndrome therapies as Urovant Science’s vibegron fails in a Phase II trial, likely spelling the end for the investigational indication.
Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.